I wonder to what extent the pharmas are lining up on either side, hedging their bets, or just couldn't give a damn...
from Deltagen 10Q
"We had DeltaSelect agreements as of September 30, 2000 with the following companies: Glaxo Wellcome, Merck & Co., Pfizer, Inc., Roche Biosciences and Schering-Plough Research Institute...
...We anticipate that the majority of our future revenues will be derived from periodic subscription fees under agreements with subscribers to our DeltaBase-TM- gene function database. However, Glaxo Wellcome is currently our only subscriber to DeltaBase...
... The decrease in third quarter revenue was related entirely to revenue associated with agreements for the development and analysis of knockout mice. In the third quarter of 2000 and 1999, all of our revenue came from contracts with Merck, Pfizer, Roche, Schering-Plough and Tularik. Our contract with Schering-Plough produced no revenue in 1999. Our Tularik agreement expired in February 2000. .."
Lexicon recent quarterly results -
"....Current sublicensees under the
positive-negative selection and/or isogenic DNA patents include American
Home Products, Amgen Inc., Bristol-Myers Squibb Company, DuPont
Pharmaceuticals Company, Genentech, Inc., Ligand Pharmaceuticals,
Millennium Pharmaceuticals, Inc., Pfizer, Inc., Roche Bioscience and
Schering-Plough Research Institute....
...Lexicon has established drug discovery collaborations with Abgenix, Inc. and Arena Pharmaceuticals, Inc., a LexVision (TM) collaboration with Bristol-Myers Squibb Company, and functional genomics and OmniBank alliances with many pharmaceutical and biotechnology companies, including American Home Products, Boehringer Ingelheim Pharmaceuticals, DuPont Pharmaceuticals Company, Millennium Pharmaceuticals, Inc., N.V. Organon, Pharmacia Corp. and The R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson, as well as leading academic institutions worldwide..." |
